Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Department of Neurology and Clinical Neurophysiology, University Hospital of Augsburg, Augsburg, Germany.
Blood. 2022 Jul 7;140(1):73-77. doi: 10.1182/blood.2021014588.
Kanack and colleagues analyze anti-platelet factor 4 antibodies from 5 patients with vaccine-induced thrombotic thrombocytopenia (VITT) secondary to COVID-19 adenoviral vaccination and antibodies from patients with spontaneous heparin-induced thrombocytopenia (HIT) and classical HIT. VITT antibodies are monoclonal or oligoclonal, similar to spontaneous HIT, whereas classical HIT antibodies are polyclonal. Heparin inhibits antibody-induced platelet activation in VITT, suggesting that heparin should be considered for the treatment of VITT.
卡纳克及其同事分析了 5 例因 COVID-19 腺病毒疫苗接种而导致的疫苗诱导的血栓性血小板减少症 (VITT) 的抗血小板因子 4 抗体，以及自发性肝素诱导的血小板减少症 (HIT) 和经典 HIT 患者的抗体。VITT 抗体是单克隆或寡克隆的，与自发性 HIT 相似，而经典 HIT 抗体是多克隆的。肝素抑制 VITT 中抗体诱导的血小板激活，这表明肝素应考虑用于 VITT 的治疗。
